Pf Magazine

19/06/2024

The impact of EU pharmaceutical reform - Pf Media https://bit.ly/3KQBWMQ

The conversation around the proposed EU pharmaceutical legislation and incoming HTA reform was held against the backdrop of the EU elections.

06/06/2024

Go-to-market innovation in 2028: Essential disruption dimensions for thriving in the new European healthcare landscape - Pf Media https://bit.ly/3RcqP4s

The European healthcare market is poised for significant disruption, with evolving consumer demands and new competitive forces.

06/06/2024

Go-to-market innovation in 2028: Essential disruption dimensions for thriving in the new European healthcare landscape - Pf Media https://bit.ly/3Vw2Mjm

15/05/2024

Dare to be disruptive – how to model your European go to market strategy for success - Pf Media https://bit.ly/3ytkpat

Nick Bartlett, Head of Consulting at Uniphar, shares key takeaways from his workshop at Reuters Pharma 2024 in Barcelona.

02/05/2024

Novartis' leukaemia treatment to be made available on the NHS - Pf Media https://bit.ly/44qLjvz

NICE recommends personalised immunotherapy for children and young adults to fight a form of leukaemia be made available on the NHS.

25/04/2024

NICE recommends new Novartis treatment for brain tumours - Pf Media https://bit.ly/44hxqQu

NICE recommends new Novartis treatment for children and young people in England and Wales, with an aggressive form of brain tumour.

18/04/2024

Promising new treatment strategy for aggressive form of leukaemia - Pf Media https://bit.ly/4463eb5

A promising treatment strategy for an aggressive type of leukaemia – Acute myeloid leukaemia (AML) – has been uncovered.

28/03/2024

Positive trial results for PharmNovo's pain management drug - Pf Media https://bit.ly/4ctCIMx

PharmNovo's trial from Phase I of its neuropathic pain management drug candidate has given positive results in the feedback.

27/03/2024

Research uncovers how to target dormant breast cancer cells and prevent relapse - Pf Media https://bit.ly/3Tyle8T

Scientists have discovered how breast cancer cells can ‘hibernate’ to avoid treatment and ‘wake up’ years later – causing a relapse.

21/03/2024

HCP engagement solutions – being present isn’t enough - Pf Media https://bit.ly/4cthz4U

Have you invested in digital engagement of HCPs? When it comes to engaging healthcare professionals online, being present isn’t enough.

15/03/2024

Almirall expands pipeline to rare dermatological diseases - Pf Media:
https://bit.ly/48VLPCv

Almirall and Eloxx Pharmaceuticals have agreed an exclusive license agreement for the asset ZKN-013, in use for rare dermatological diseases.

15/03/2024

SMC accepts AbbVie’s new Parkinson’s drug within NHS Scotland - Pf Media
https://bit.ly/3TBz8Ix

The Scottish Medicines Consortium (SMC) has accepted AbbVie's new Parkinson's drug for restricted use within NHS Scotland.